Intratumoral drug delivery with nanoparticulate carriers.
about
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesNANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure.Single particle tracking reveals biphasic transport during nanorod magnetophoresis through extracellular matrixConjugation of pH-responsive nanoparticles to neural stem cells improves intratumoral therapy.Off to the organelles - killing cancer cells with targeted gold nanoparticles.Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancerEffect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells.Evaluating the pharmacokinetics and in vivo cancer targeting capability of Au nanocages by positron emission tomography imaging.Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities.Nanoparticle characterization: state of the art, challenges, and emerging technologies.Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancerEngineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo.Core-shell nanocarriers for cancer therapy. Part I: biologically oriented design rules.Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles.Plasma and cellular pharmacokinetic considerations for the development and optimization of antitumor block copolymer micelles.Mathematical modeling analysis of intratumoral disposition of anticancer agents and drug delivery systems.In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles.Loco-regional administration of nanomedicines for the treatment of lung cancer.Cancer drug delivery in the nano era: An overview and perspectives (Review)Doxorubicin Conjugated to Glutathione Stabilized Gold Nanoparticles (Au-GSH-Dox) as an Effective Therapeutic Agent for Feline Injection-Site Sarcomas-Chick Embryo Chorioallantoic Membrane Study.Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy.Fabrication of dendrimer-releasing lipidic nanoassembly for cancer drug delivery.Albumin-Gold Nanorod Nanoplatform for Cell-Mediated Tumoritropic Delivery with Homogenous ChemoDrug Distribution and Enhanced Retention AbilityTumor-activated prodrug (TAP)-conjugated nanoparticles with cleavable domains for safe doxorubicin delivery.A Multilayered Cell Culture Model for Transport Study in Solid Tumors: Evaluation of Tissue Penetration of Polyethyleneimine Based Cationic Micelles.Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts.Subcutaneous administration of nano- and microsuspensions of poorly soluble compounds to rats.Preventing Obstructions of Nanosized Drug Delivery Systems by the Extracellular Matrix.Thermodynamic compatibility of actives encapsulated into PEG-PLA nanoparticles: In Silico predictions and experimental verification.Vincristine liposomes with smaller particle size have stronger diffusion ability in tumor and improve tumor accumulation of vincristine significantly.Effect of shape, size, and aspect ratio on nanoparticle penetration and distribution inside solid tissues using 3D spheroid models.Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model.Multifunctional Liposomes for Image-Guided Intratumoral Chemo-Phototherapy.Particle morphology: an important factor affecting drug delivery by nanocarriers into solid tumors.Breaching the Hyaluronan Barrier with PH20-Fc Facilitates Intratumoral Permeation and Enhances Antitumor Efficiency: A Comparative Investigation of Typical Therapeutic Agents in Different Nanoscales.Tumor Microenvironment Targeted Nanotherapy
P2860
Q26828930-2FD3150E-C85C-4A82-A7A4-493E2B49CE3AQ28078448-AB7661FE-B856-4AE8-A048-D0C10C868191Q30443689-00661560-936D-4FD9-AB85-DBE044D249E5Q30607882-49663A61-299B-4A6D-A3DD-8B78F9B28362Q34145424-A6DC57DC-7708-4DA1-AD7E-678E078B72F0Q35086507-03B2E071-7942-4422-A179-3705E634705FQ35598295-E04956F4-EB78-443A-AFDB-119D373734D1Q35972741-2020C275-8CDB-4776-B23D-DBC6E29E107FQ36113655-1C68C90A-ACCC-4E25-957F-D48571681226Q36803827-407E22CA-80C2-42F8-B8C7-29D01EC1A122Q36901928-25C6FACB-786A-44D9-B9AA-CEBBE2A9537FQ37426564-DC0F06EA-437C-45DC-BED5-01EE0E7292C7Q37634520-CFEA4B5F-918C-49BC-935D-0C63B9CE12C0Q38169195-FFBCE95D-FE2F-4525-BF88-A630C03B9EB4Q38228652-CBD7FCCF-8156-45B9-AD48-FD8281083A08Q38248809-45511583-A14D-49AA-B29E-150F2BD720EDQ38392523-FD212331-B8D9-49CF-9A58-C1659E04FBC7Q38405765-998406F5-DC0F-4EC7-97DE-01641B77B544Q38639228-2C8743F0-242D-4140-9504-7D124D6E4954Q38669454-BDA0F2D0-A915-4EEE-A00F-1F86A490AF12Q38716160-024EB24C-BFDB-47A4-9800-3F894D87DC97Q38776676-80F77AE8-FF5F-4678-AAEC-FCC2FAE2725DQ38777471-90CF4B1B-09A0-4493-9E98-CDDEF799E65CQ38945119-E50F5AF4-FA95-415B-897F-6634F45DFB2CQ38956549-8C741404-6143-4561-B94A-5EDD4FE8F058Q39313613-5575E993-DA9C-4DA8-9634-F30CFBFD4BEFQ41215905-86BA6147-A068-456E-BAE6-481A2C21FEA5Q44888499-F6C69B83-7929-4DE6-A771-1F22313F65FAQ46264786-59528AA2-4D56-41BB-B1AE-930AD2A9BAFFQ46515239-E860918C-AE8B-4AE0-A915-168CC521CAA4Q47156854-01F129B3-5AE8-41A2-82C2-DEA1D0E0571CQ47361903-62C48189-9C02-4AD2-BF98-946BCF420D74Q47645697-A54C97BD-D354-41E1-8907-C69159C78478Q48145022-767F62A4-A37E-4A45-B593-66ED02E0BFBAQ49628457-B37D0755-D252-413A-AFC7-DA3934C93F33Q51152292-7FB8966A-E8DE-4FA6-B38E-8F951E738472Q59133567-5BAED17E-8A64-421B-87A0-026331F73F48
P2860
Intratumoral drug delivery with nanoparticulate carriers.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Intratumoral drug delivery with nanoparticulate carriers.
@ast
Intratumoral drug delivery with nanoparticulate carriers.
@en
type
label
Intratumoral drug delivery with nanoparticulate carriers.
@ast
Intratumoral drug delivery with nanoparticulate carriers.
@en
prefLabel
Intratumoral drug delivery with nanoparticulate carriers.
@ast
Intratumoral drug delivery with nanoparticulate carriers.
@en
P2860
P1476
Intratumoral drug delivery with nanoparticulate carriers.
@en
P2093
Hillary Holback
P2860
P304
P356
10.1007/S11095-010-0360-Y
P577
2011-01-07T00:00:00Z